ALFA Finder| Revenue growth | FY26 revenue up 17% YoY; Q4 revenue up 22% YoY. |
|---|---|
| Margins | EBITDA margins stable at 31%; PAT margin improved to 23%. |
| Demand visibility | Strong demand in Human Healthcare; US market remains challenging but steady. |
| Management confidence | Balanced confidence despite highlighting significant global geopolitical and inflationary headwinds. |
Growth
FY26 revenue grew 17% YoY. Q4 revenue surged 22% YoY, primarily volume-led by the Human Healthcare and Specialized Manufacturing segments.
Outlook
Targeting steady double-digit growth in FY27. R&D center in Nashik becomes fully operational in H2 FY27.
Risks
Inflation in fuel, salt, and solvents; high US market competition; and potential margin compression from rising input costs.
Earnings Call filed with BSE, NSE: ADVENZYMES. Summary written with AI assistance from the document.
Advanced Enzyme Technologies Ltd: key numbers
- Share price
- ₹283.85
- Market cap
- ₹3,178 Cr
- Revenue (annual)
- ₹745.8 Cr
- Net profit (annual)
- ₹168.7 Cr
- P/E (TTM)
- 18.6×Sector 43.8×
- Promoter holding
- 43.56%+0.32% QoQ
- FII holding
- 26.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Advanced Enzyme Technologies Ltd
All →Advanced Enzyme Technologies Earnings Call Transcript: Key Takeaways
Clean headline: revenue +16% YoY, EBITDA 34%, PAT +14%. Growth leans on deferred sales and rising top-10 customer concentration (46%). US recovery is only hoped for.
Advanced Enzyme Technologies Promoter Reclassification
Advanced Enzyme Technologies applied to exchanges to reclassify 13 promoter group members as public under Regulation 31A. They hold 59,000 shares combined, about 0.05%.
Advanced Enzyme Technologies Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹2,145mn (+16% YoY), EBITDA ₹721mn (+20%, 34% margin), PAT ₹512mn (+14%). H1 revenue +10%, PAT +5%. Industrial bio-processing and animal nutrition lead growth.
Advanced Enzyme Technologies Results Update
Advanced Enzyme Technologies issued a press release highlighting unaudited Q2 and half-year FY27 results. Revenue and profit grew year-on-year, with EBITDA and PAT margins reported.
Advanced Enzyme Technologies Q2 FY27 Results: Net Profit ₹51.2 Cr, Up 14.5% YoY
Advanced Enzyme Technologies Ltd reported revenue from operations of ₹214.5 Cr (+16.3% YoY) and net profit of ₹51.2 Cr (+14.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.2 Cr · +14.5% YoY
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme closed its buyback after purchasing 2,410,906 shares for ₹69.70 Crore. Closure took effect October 30, 2026, ahead of the scheduled period.
- Value
- ₹69.70 Cr
- Execution
- August 14, 2026 to October 30, 2026